Matthew Ronsheim
Corporate Officer/Principal bei ENTASIS THERAPEUTICS HOLDINGS INC.
Vermögen: 621 457 $ am 31.03.2024
Profil
Matthew Ronsheim is currently the Chief Pharmaceutical Sciences Officer at Entasis Therapeutics Holdings, Inc. Prior to this, he was the Executive Director & Head-Chemistry Manufacturing at Enanta Pharmaceuticals, Inc. from 2016 to 2019.
He received his undergraduate degree from Southern Connecticut State University and his doctorate from the University of New Hampshire.
Bekannte Unternehmensbeteiligungen
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
INNOVIVA, INC.
0,06% | 05.03.2024 | 40 778 ( 0,06% ) | 621 457 $ | 31.03.2024 |
Aktive Positionen von Matthew Ronsheim
| Unternehmen | Position | Beginn |
|---|---|---|
| ENTASIS THERAPEUTICS HOLDINGS INC. | Corporate Officer/Principal | 01.09.2020 |
Ehemalige bekannte Positionen von Matthew Ronsheim
| Unternehmen | Position | Ende |
|---|---|---|
| ENANTA PHARMACEUTICALS, INC. | Director/Board Member | 01.08.2019 |
Ausbildung von Matthew Ronsheim
| Southern Connecticut State University | Undergraduate Degree |
| University of New Hampshire | Doctorate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 1 |
|---|---|
| ENANTA PHARMACEUTICALS, INC. | Health Technology |
| Private Unternehmen | 1 |
|---|---|
Entasis Therapeutics Holdings, Inc.
 Entasis Therapeutics Holdings, Inc. BiotechnologyHealth Technology Entasis Therapeutics Holdings, Inc. operates as a clinical stage biopharmaceutical company. It focuses on the discovery and development of novel antibacterial products for serious drug-resistant bacterial infections. Its anti-infective discovery platform has produced a pipeline of differentiated programs, which is bacterial infections, including ETX2514SUL (targeting Acinetobacter baumannii infections), ETX0282CPDP (targeting Enterobacteriaceae infections), Non-Beta-lactam PBP inhibitor, and Zoliflodacin. The company was founded in May 2015 and is headquartered in Waltham, MA. | Health Technology |
